Inovio Pharmaceuticals (NASDAQ:INO) Stock Crosses Above 200 Day Moving Average – What’s Next?

Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.05 and traded as high as $2.37. Inovio Pharmaceuticals shares last traded at $2.26, with a volume of 2,789,118 shares.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. Zacks Research downgraded shares of Inovio Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, September 3rd. Piper Sandler reaffirmed an “overweight” rating and set a $6.00 target price (up previously from $5.00) on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. UBS Group reissued an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Citigroup restated a “market outperform” rating on shares of Inovio Pharmaceuticals in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a research note on Monday. Five analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $9.00.

Inovio Pharmaceuticals Trading Up 12.1%

The stock has a 50-day simple moving average of $2.19 and a two-hundred day simple moving average of $2.06. The firm has a market capitalization of $173.50 million, a P/E ratio of -1.00 and a beta of 1.54.

Inovio Pharmaceuticals (NASDAQ:INO) last released its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.07. As a group, research analysts expect that Inovio Pharmaceuticals, Inc. will post -4.23 EPS for the current year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Several institutional investors have recently bought and sold shares of INO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 5,894 shares during the period. Bank of Montreal Can lifted its stake in shares of Inovio Pharmaceuticals by 23.7% during the 2nd quarter. Bank of Montreal Can now owns 57,946 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 11,110 shares during the last quarter. MCF Advisors LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 3rd quarter worth $26,000. SG Americas Securities LLC bought a new stake in Inovio Pharmaceuticals during the third quarter valued at about $27,000. Finally, Stephens Inc. AR purchased a new position in Inovio Pharmaceuticals in the third quarter valued at about $32,000. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.